|
1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Suppliers list
|
| Company Name: |
BOC Sciences
|
| Tel: |
1-631-485-4226; 16314854226 |
| Email: |
info@bocsci.com |
| Products Intro: |
Product Name:PRMT5-IN-3
CAS:2159123-14-3
Purity:>=96% Remarks:Reach out to us for more information about custom solutions.
|
| Company Name: |
TargetMol Chemicals Inc.
|
| Tel: |
4008200310 15002144251 |
| Email: |
marketing@tsbiochem.com |
| Products Intro: |
Product Name:PRMT5-IN-3
CAS:2159123-14-3
Package:25mg/RMB 10600;100mg/RMB 17500;50mg/RMB 13800
|
| Company Name: |
Shanghai Tachizaki Biomedical Research Center
|
| Tel: |
18014399201 |
| Email: |
sales@chemlab-tachizaki.com |
| Products Intro: |
Product Name:PF-06939999/PRMT5-IN-3
CAS:2159123-14-3
Purity:98%+ HPLC Package:10mg，100mg，500mg，1g，2g，5g+
|
|
| | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Basic information |
| Product Name: | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- | | Synonyms: | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)-;(1S,2S,3S,5R)-3-([6-(difluoromelhyl)-5-fluoro-1,2l3,4-tetrahydroisoquinolin-8-yl]oxy}-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)cyclopentane-1,2-diol;PF-06939999/PRMT5-IN-3;PRMT5-IN-3 | | CAS: | 2159123-14-3 | | MF: | C22H23F3N4O3 | | MW: | 448.44 | | EINECS: | | | Product Categories: | | | Mol File: | 2159123-14-3.mol | ![1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Structure](CAS/20210305/GIF/2159123-14-3.gif) |
| | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Chemical Properties |
| Boiling point | 572.5±50.0 °C(Predicted) | | density | 1.61±0.1 g/cm3(Predicted) | | pka | 12.86±0.70(Predicted) | | form | Solid | | color | White to off-white |
| | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Usage And Synthesis |
| Uses | PF-06939999 (PRMT5-IN-3) is a SAM-competitive, orally active PRMT5 inhibitor that inhibits the expression of SDMA protein (IC50 in A427 is 1.1 nM), exhibits synthetic lethality to tumor cells but produce few side effects combined with DNA damaging agents[1][2]. | | in vivo | PF-06939999 (3-30 mg/kg, po, once a day for 36-44 days) exhibits antitumor effect in mouse A427 or NCI-H441 xenograft models[2]. | Animal Model: | Mouse A427 or NCI-H441 xenograft models[2] | | Dosage: | 3-30 mg/kg | | Administration: | po, once a day for 36-44 days | | Result: | Inhibited tumor growth. |
| | IC 50 | PRMT5 | | References | [1] Adli M. Combinatorial drug treatment of cancer. WO2020198601A1.
[2] Jensen-Pergakes K, et al., SAM-Competitive PRMT5 Inhibitor PF-06939999 Demonstrates Antitumor Activity in Splicing Dysregulated NSCLC with Decreased Liability of Drug Resistance. Mol Cancer Ther. 2022 Jan;21(1):3-15. DOI:10.1158/1535-7163.MCT-21-0620 |
| | 1,2-Cyclopentanediol, 3-[[6-(difluoromethyl)-5-fluoro-1,2,3,4-tetrahydro-8-isoquinolinyl]oxy]-5-(4-methyl-7H-pyrrolo[2,3-d]pyrimidin-7-yl)-, (1S,2S,3S,5R)- Preparation Products And Raw materials |
|